Bilimsel çalışmalar

Uzm. Dr. Hakan Taban

54 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Açık erişimli tam metinKaynak: OpenAlex

  2. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15186966 PMID 42795739 Açık erişimli tam metinKaynak: ORCID

  3. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62091702 PMID 42796309 Açık erişimli tam metinKaynak: ORCID

  4. Synchronous Adrenocortical Carcinoma, Renal Cell Carcinoma, and Mediastinal Mature Teratoma with Heterozygous Variants in SMARCA4, APC, and MYBP3: A Case Report

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-10-7 Açık erişimli tam metinKaynak: ORCID

  5. Prognostic Significance of SULF2 Expression in Surgically Resected Non-Small Cell Lung Cancer

    Medical sciences (Basel, Switzerland), 2026

    DOI 10.3390/medsci14020215 PMID 42201007 Açık erişimli tam metinKaynak: Europe PMC

  6. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Açık erişimli tam metinKaynak: OpenAlex

  7. Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel

    Medicina, 2025

    DOI 10.3390/medicina61061105 PMID 40572794 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  8. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach

    Cancers, 2025

    DOI 10.3390/cancers17020233 PMID 39858018 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  9. Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas

    Journal of Current Hematology & Oncology Research, 2025

    DOI 10.51271/jchor-0062 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  10. Prognostic value of the StAN score in elderly small cell lung cancer

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-08115-x PMID 40604202 Açık erişimli tam metinKaynak: OpenAlex

  11. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

    Acta Medica, 2025

    DOI 10.32552/2025.actamedica.1159 Açık erişimli tam metinKaynak: OpenAlex

  12. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2403051 PMID 39257075 2 atıf (Europe PMC) Kaynak: OpenAlex

  13. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

    European Archives of Oto-Rhino-Laryngology, 2024

    DOI 10.1007/s00405-024-08744-4 PMID 38795147 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  14. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e18004 Kaynak: ORCID

  15. Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy

    Cancers, 2024

    DOI 10.3390/cancers16051061 PMID 38473418 9 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  16. Challenges in using tumor mutational burden as a post-treatment biomarker

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.103999 PMID 39561622 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  17. 1271P Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1328 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  18. Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Clinics and Research in Hepatology and Gastroenterology, 2023

    DOI 10.1016/j.clinre.2023.102171 PMID 37352926 19 atıf (OpenAlex) Kaynak: OpenAlex

  19. The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients

    Cureus, 2023

    DOI 10.7759/cureus.44016 PMID 37746394 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  20. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

    Clinics and Research in Hepatology and Gastroenterology, 2023

    DOI 10.1016/j.clinre.2023.102091 PMID 36738855 Kaynak: OpenAlex

  21. Treatment selection for T4 laryngeal cancer: is organ-preserving approach possible with chemoradiotherapy or is multimodality treatment more effective?

    Journal of Medicine and Palliative Care, 2023

    DOI 10.47582/jompac.1314922 Açık erişimli tam metinKaynak: OpenAlex

  22. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

    South Asian Journal of Cancer, 2022

    DOI 10.1055/s-0042-1755467 PMID 36756104 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  23. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

    Journal of Clinical Medicine, 2022

    DOI 10.3390/jcm11175171 PMID 36079101 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  24. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

    Cureus, 2022

    DOI 10.7759/cureus.27828 PMID 36106272 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  25. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-92230 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  26. Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0717 PMID 34726480 7 atıf (Europe PMC) Kaynak: OpenAlex

  27. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.321 1 atıf (OpenAlex) Kaynak: OpenAlex

  28. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

    Turkish journal of urology, 2021

    DOI 10.5152/tud.2021.20377 PMID 33819441 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  29. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors

    Biomarkers in medicine, 2021

    DOI 10.2217/bmm-2020-0674 PMID 34397271 8 atıf (Europe PMC) Kaynak: Europe PMC

  30. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05702-8 PMID 32851486 10 atıf (Europe PMC) Kaynak: ORCID

  31. PILE: a candidate prognostic score in cancer patients treated with immunotherapy

    Clinical and Translational Oncology, 2021

    DOI 10.1007/s12094-021-02560-6 PMID 33586122 24 atıf (Europe PMC) Kaynak: ORCID

  32. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-021-06139-3 PMID 33709186 20 atıf (Europe PMC) Kaynak: ORCID

  33. 456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.977 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  34. Adjuvant Treatment with Paclitaxel Plus Trastuzumab for Node-Negative Breast Cancer: Real-Life Experience

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0303 PMID 34758639 4 atıf (OpenAlex) Kaynak: OpenAlex

  35. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211045909 PMID 34628993 2 atıf (OpenAlex) Kaynak: OpenAlex

  36. İleri Evre Panreatiko Biliyer Sistem Tümörlerinde Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2021

    Kaynak: OpenAlex

  37. Abstract PS10-52: Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps10-52 Kaynak: OpenAlex

  38. 173P What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.454 Açık erişimli tam metinKaynak: OpenAlex

  39. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900908 PMID 32054412 9 atıf (Europe PMC) Kaynak: OpenAlex

  40. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219877234 PMID 31566114 10 atıf (Europe PMC) Kaynak: ORCID

  41. CANCER EPIDEMIOLOGY IN ELDERLY PATIENTS

    Turkiye Klinikleri eBooks, 2020

    DOI 10.5336/978-625-401-191-7_p1 1 atıf (OpenAlex) Kaynak: OpenAlex

  42. Evaluation of emergency department visits in patients treated with immune checkpoint inhibitors.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e24160 1 atıf (OpenAlex) Kaynak: OpenAlex

  43. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

    Clinical Colorectal Cancer, 2020

    DOI 10.1016/j.clcc.2020.02.011 PMID 32224043 Kaynak: OpenAlex

  44. 1546P Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.08.2029 Açık erişimli tam metinKaynak: OpenAlex

  45. 1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.08.1827 Açık erişimli tam metinKaynak: OpenAlex

  46. 98P Low prognostic nutritional index is independently associated with poorer survival in patients receiving immune checkpoint inhibitors

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.10.587 Açık erişimli tam metinKaynak: OpenAlex

  47. Yaşlılarda Kanser Epidemiyolojisi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2020

    Kaynak: OpenAlex

  48. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

    Journal of Oncology Pharmacy Practice, 2019

    DOI 10.1177/1078155219883004 PMID 31653193 17 atıf (Europe PMC) Kaynak: OpenAlex

  49. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.15_suppl.e22557 Kaynak: OpenAlex

  50. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz261.017 Açık erişimli tam metinKaynak: OpenAlex